Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
MCT’s collaboration with Onxeo on HCC Phase III study in Middle East
Related Posts
-
MCT Director of Clinical operations ...
Read more... -
Ivory Coast offers a very interesting ...
Read more... -
Marwan Felaefel (Clinical Project ...
Read more... -
MCT will organize a Webinar on ...
Read more... -
MCT is pleased to communicate about ...
Read more... -
Onxeo has engaged MCT (Regional CRO ...
Read more... -
22 MCT team members coming from ...
Read more... -
All MCT Country Managers were ...
Read more... -
MCT is looking for Senior Clinical ...
Read more... -
26 MCT team members coming from ...
Read more... -
MCT CRA Mariana Alnazer has written ...
Read more... -
MCT inaugurates in March 15 it new ...
Read more... -
MCT Quality Manager Alexa Younes has ...
Read more... -
MCT quality department is welcoming a ...
Read more...
